Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
Mareque M, Montesinos P, Font P, et al. Clinicoecon Outcomes Res. 2021;13:263–277. Page 271, Results, Base Case, second line from the bottom, the text “€ 15,134” should read “€ 151,434”. The authors apologize for this error. Read the original article
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2021-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|